Suppr超能文献

抗 T 淋巴细胞球蛋白(ATLG)与移植后环磷酰胺相比,用于预防 ALL 患者异基因造血干细胞移植后移植物抗宿主病。

Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation.

机构信息

Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.

University Hospital of Internal Medicine V (Hematology and Oncology), Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria.

出版信息

Bone Marrow Transplant. 2024 Sep;59(9):1265-1274. doi: 10.1038/s41409-024-02328-w. Epub 2024 Jun 14.

Abstract

We retrospectively analyzed high-risk ALL patients in CR1 receiving total body irradiation based conditioning regimen with ATLG (n = 74) or PTCy (n = 73) for GVHD prophylaxis. The 3-year OS and LFS were similar in both groups: 65 and 60% in the ATLG group and 64 and 67% in the PTCy group (p = 0.9 and 0.5, respectively). CIR and NRM rate at three years was 12 and 21% after PTCy and 19 and 20% after ATLG (p = 0.4 and p = 0.9, respectively). Acute GvHD grades II-IV and grades III/IV at 100 days was 46 and 19% after PTCy and 33 and 10% after ATLG (p = 0.08 and p = 0.9, respectively). Chronic GvHD of all grade at two years was higher after PTCy: 55% versus 26% (p < 0.001). Based on the propensity score matching (PSM) analysis, aGvHD grades II-IV was trending higher in the PTCy group compared to the ATLG group (p = 0.07). In contrast to the PSM analysis, on multivariate analysis the receipt of PTCy compared with ATLG was associated with a reduced CIR (p = 0.026). Our retrospective single-center analysis shows a lower incidence of acute and chronic GvHD while displaying similar LFS and OS after ATLG compared to PTCy in TBI based allogeneic stem cell transplantation for high-risk ALL.

摘要

我们回顾性分析了在 CR1 接受全身照射(TBI)为基础预处理方案,并用 ATLG(n=74)或 PTCy(n=73)预防移植物抗宿主病(GVHD)的高危 ALL 患者。两组患者的 3 年 OS 和 LFS 相似:ATLG 组为 65%和 60%,PTCy 组为 64%和 67%(p=0.9 和 0.5)。PTCy 和 ATLG 组 3 年 CIR 和 NRM 率分别为 12%和 21%,19%和 20%(p=0.4 和 p=0.9)。PTCy 和 ATLG 组 100 天的急性 GVHD Ⅱ-Ⅳ级和Ⅲ/Ⅳ级分别为 46%和 19%,33%和 10%(p=0.08 和 p=0.9)。PTCy 组 2 年时所有等级的慢性 GVHD 更高:55%比 26%(p<0.001)。基于倾向评分匹配(PSM)分析,PTCy 组的 aGVHD Ⅱ-Ⅳ级较 ATLG 组有升高趋势(p=0.07)。与 PSM 分析相反,多变量分析显示与 ATLG 相比,接受 PTCy 与 CIR 降低相关(p=0.026)。我们的回顾性单中心分析显示,在接受 TBI 为基础的异基因干细胞移植治疗高危 ALL 时,与 PTCy 相比,ATLG 组的急性和慢性 GVHD 发生率较低,而 LFS 和 OS 相似。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7386/11368809/5fc59fb31b95/41409_2024_2328_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验